Zai Lab Announces NDA Acceptance of Repotrectinib for Patients with ROS1-positive NSCLC by China’s NMPA Read more about Zai Lab Announces NDA Acceptance of Repotrectinib for Patients with ROS1-positive NSCLC by China’s NMPA
Zai Lab and Novocure Announce LUNAR Phase 3 Clinical Trial Demonstrates Statistically Significant and Clinically Meaningful Extension in Overall Survival for Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies Read more about Zai Lab and Novocure Announce LUNAR Phase 3 Clinical Trial Demonstrates Statistically Significant and Clinically Meaningful Extension in Overall Survival for Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies
Zai Lab to Highlight New Data from its Oncology Pipeline at 2023 ASCO Annual Meeting Read more about Zai Lab to Highlight New Data from its Oncology Pipeline at 2023 ASCO Annual Meeting
Zai Lab Announces Participation in June Investor Conferences - TC Read more about Zai Lab Announces Participation in June Investor Conferences - TC
Zai Lab Announces That Repotrectinib Granted Priority Review by China’s NMPA Read more about Zai Lab Announces That Repotrectinib Granted Priority Review by China’s NMPA
Zai Lab Announces Strategic Partnership and Global License Agreement with MediLink Therapeutics for a Next Generation Antibody-Drug Conjugate Program in Oncology - TC Read more about Zai Lab Announces Strategic Partnership and Global License Agreement with MediLink Therapeutics for a Next Generation Antibody-Drug Conjugate Program in Oncology - TC
Zai Lab to Announce First Quarter 2023 Financial Results and Corporate Updates on May 9, 2023 Read more about Zai Lab to Announce First Quarter 2023 Financial Results and Corporate Updates on May 9, 2023
Zai Lab Statement on Silicon Valley Bank (“SVB”) and Joint US Federal Agency Announcement Read more about Zai Lab Statement on Silicon Valley Bank (“SVB”) and Joint US Federal Agency Announcement
Zai Lab Announces Participation in March Investor Conferences Read more about Zai Lab Announces Participation in March Investor Conferences
Zai Lab to Present Two New Phase 3 Analyses for Niraparib in Ovarian Cancer at the 2023 ESMO Gynaecological Cancers Congress Read more about Zai Lab to Present Two New Phase 3 Analyses for Niraparib in Ovarian Cancer at the 2023 ESMO Gynaecological Cancers Congress